Objective: The purpose of this article is to evaluate the incidence of contrast-induced nephropathy (CIN) and the effects of associated risk factors in patients with multiple myeloma undergoing contrast-enhanced CT (CECT) with IV administration of nonionic iodinated contrast agent.

Materials And Methods: This retrospective review of medical records identified patients with a diagnosis of myeloma who underwent a CECT examination of the chest, abdomen, or pelvis between January 1, 2005, and December 1, 2008. Analysis for CIN, as defined by an increase in creatinine level after the CECT examination of 25% or more, or of 0.5 mg/dL, compared with the level before the CECT examination, both within 48 hours and within 7 days, was performed. Statistical correlations between the development of CIN and creatinine level before CECT examination, patient location, type and amount of contrast agent, blood urea nitrogen-creatinine ratio, history of diabetes, hypercalcemia, Bence Jones proteinuria, β(2)-microglobulin level, albumin level, International Myeloma Staging System stage, and history of myeloma provided at the time the CT examination was ordered were calculated.

Results: Forty-six patients who completed 80 unique examinations were included; their average creatinine level before CECT examination was 0.97 mg/dL. There was no significant difference in the average creatinine levels before CT examination between patients without and those with CIN. Four (5%) and 12 (15%) patients developed CIN within 48 hours and 7 days, respectively. Only serum β(2)-microglobulin level showed a statistically significant (p = 0.03) correlation with the development of CIN.

Conclusion: The incidence of CIN in patients with multiple myeloma with a normal creatinine level is low and correlates with β(2)-microglobulin levels. The administration of contrast agent in this patient population is safe but should be based on the potential benefit of the examination and the expected low risk of developing CIN.

Download full-text PDF

Source
http://dx.doi.org/10.2214/AJR.10.5152DOI Listing

Publication Analysis

Top Keywords

cect examination
20
creatinine level
16
level cect
16
patients multiple
12
multiple myeloma
12
incidence contrast-induced
8
contrast-induced nephropathy
8
myeloma undergoing
8
undergoing contrast-enhanced
8
examination
8

Similar Publications

Background: Renal cell carcinoma (RCC), the most common malignant renal tumor, is primarily treated by surgical resection, including radical nephrectomy (RN) and partial nephrectomy (PN). At present, the choice of surgery mainly depends on the comprehensive evaluation of patients' clinical data, including histological classification, such as clear cell renal cell carcinoma (ccRCC) and non-clear cell renal cell carcinoma (nccRCC), and RENAL (radius, exophytic/endophytic, nearness, anterior/posterior, and location) score. Compared with biopsy and contrast-enhanced computed tomography (CECT), contrast-enhanced ultrasound (CEUS) is safer and less invasive.

View Article and Find Full Text PDF

Objective: To explore the imaging manifestations and clinical application value of contrast-enhanced ultrasound (CEUS) in liver metastases of middle and low rectal cancer by performing CEUS in patients. Additionally, we compared the results of CEUS with those of abdominal contrast-enhanced computed tomography (CECT) to assess the reliability of diagnosing liver metastases in patients with middle and low rectal cancer.

Methods: Hepatic CEUS was performed in 1095 patients with middle and low rectal cancer, and all patients underwent abdominal CECT examinations to determine the presence or absence of liver metastases.

View Article and Find Full Text PDF

Malignant melanoma is third most common cause of brain metastasis after lung and breast cancer. Most patients with brain metastases from malignant melanoma are diagnosed after treatment for known extracranial metastases and have a poor outcome despite various local and systemic therapeutic approaches. Here we discuss an unusual case of a 61-year-old male patient who presented with a brain metastasis as the initial disease presentation and the presumed primary lesion was later found in the gastrointestinal tract and the scalp.

View Article and Find Full Text PDF

Marginal Mandibulectomy in Oral Cavity SCC: Experience in a Tertiary Care Centre.

Indian J Otolaryngol Head Neck Surg

December 2024

Department of Surgical Oncology, Madras Medical College, Rajiv Gandhi Govt. General Hospital, Chennai, Tamil Nadu India.

Marginal mandibulectomy is indicated for oral cavity squamous cell carcinomas that involve floor of mouth, abut or minimally erode the mandible without gross invasion. Successful outcomes after Marginal mandibulectomy is predicated on accurate patient selection and appropriate adjuvant treatment based on specific host and tumor characteristics. To study the onclogical outcomes in terms of loco-regional recurrence free survival and disease specific survival of marginal mandibulectomy done for oral squamous cell carcinomas.

View Article and Find Full Text PDF

Objective: To study the prevalence of synchronous oesophageal cancer in patients with head and neck cancers using Narrow Band Imaging and Lugol's chromoendoscopy.

Materials And Methods: Study design: Prospective cross sectional diagnostic study. Method: 63 recruited patients with head and neck cancers, underwent haematologic evaluation, histological confirmation, imaging which included contrast enhanced computerised tomography(CECT) of the Neck and when indicated an additional Magnetic Resonance Imaging(MRI) scan followed by UGI endoscopy using white light followed by Narrow Band Imaging(NBI) and Lugol's chromoendoscopy(LCE).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!